Emergent Biosolutions, Inc. - stock earnings
EBS Upcoming estimated earnings
| Date | Actual / Estimated EPS | Low Revenue | Actual / Estimated Revenue | High Revenue |
|---|---|---|---|---|
| May 1, 2024 AfterMarket | 0.59 / -0.84 | - | 300.4 million / 226.7 million | - |
| Aug. 6, 2024 BeforeMarket | - / - | 199.0 million | - / 221.8 million | 244.5 million |
EBS Quarterly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2024Q1 | 9.0 million USD | 300.4 million USD |
| 2023Q4 | -49.5 million USD | 276.6 million USD |
| 2023Q3 | -265.9 million USD | 270.5 million USD |
| 2023Q2 | -261.3 million USD | 337.9 million USD |
| 2023Q1 | -183.0 million USD | 165.1 million USD |
| 2022Q4 | -88.0 million USD | 330.7 million USD |
| 2022Q3 | -75.7 million USD | 240.0 million USD |
| 2022Q2 | -56.4 million USD | 242.7 million USD |
| 2022Q1 | -3.7 million USD | 307.5 million USD |
| 2021Q4 | 189.3 million USD | 723.2 million USD |
| 2021Q3 | -32.7 million USD | 329.0 million USD |
| 2021Q2 | 4.6 million USD | 397.5 million USD |
| 2021Q1 | 69.7 million USD | 343.0 million USD |
| 2020Q4 | 185.4 million USD | 583.0 million USD |
| 2020Q3 | 39.5 million USD | 385.2 million USD |
| 2020Q2 | 92.7 million USD | 394.7 million USD |
| 2020Q1 | -12.5 million USD | 192.5 million USD |
| 2019Q4 | 46.9 million USD | 360.4 million USD |
| 2019Q3 | 43.2 million USD | 311.8 million USD |
| 2019Q2 | -9.5 million USD | 243.2 million USD |
| 2019Q1 | -26.0 million USD | 190.6 million USD |
| 2018Q4 | -3.4 million USD | 270.7 million USD |
| 2018Q3 | 20.9 million USD | 173.7 million USD |
| 2018Q2 | 50.1 million USD | 220.2 million USD |
| 2018Q1 | -4.9 million USD | 117.8 million USD |
| 2017Q4 | 33.9 million USD | 193.8 million USD |
| 2017Q3 | 33.6 million USD | 149.4 million USD |
| 2017Q2 | 4.6 million USD | 100.8 million USD |
| 2017Q1 | 10.5 million USD | 116.9 million USD |
| 2016Q4 | 37.4 million USD | 151.7 million USD |
| 2016Q3 | 21.3 million USD | 142.9 million USD |
| 2016Q2 | -10.9 million USD | 101.5 million USD |
| 2016Q1 | 4.0 million USD | 111.0 million USD |
| 2015Q4 | 33.3 million USD | 168.1 million USD |
| 2015Q3 | 36.9 million USD | 164.9 million USD |
| 2015Q2 | 14.1 million USD | 126.1 million USD |
| 2015Q1 | -21.5 million USD | 63.6 million USD |
| 2014Q4 | 30.1 million USD | 148.0 million USD |
| 2014Q3 | 21.8 million USD | 138.0 million USD |
| 2014Q2 | 5.0 million USD | 110.3 million USD |
| 2014Q1 | -20.2 million USD | 53.9 million USD |
| 2013Q4 | 15.2 million USD | 98.1 million USD |
| 2013Q3 | 13.5 million USD | 89.1 million USD |
| 2013Q2 | 10.5 million USD | 82.4 million USD |
| 2013Q1 | -8.1 million USD | 43.1 million USD |
| 2012Q4 | 16.1 million USD | 94.6 million USD |
| 2012Q3 | 6.6 million USD | 66.6 million USD |
| 2012Q2 | 7.6 million USD | 70.4 million USD |
| 2012Q1 | -6.8 million USD | 50.3 million USD |
| 2011Q4 | 28.7 million USD | 107.9 million USD |
| 2011Q3 | 1.5 million USD | 58.8 million USD |
| 2011Q2 | 14.2 million USD | 88.1 million USD |
| 2011Q1 | -21.4 million USD | 18.5 million USD |
| 2010Q4 | 26.2 million USD | 103.2 million USD |
| 2010Q3 | 13.1 million USD | 74.0 million USD |
| 2010Q2 | 9.8 million USD | 62.1 million USD |
| 2010Q1 | 2.5 million USD | 46.8 million USD |
| 2009Q4 | 4.2 million USD | 53.8 million USD |
| 2009Q3 | 949000 USD | 43.3 million USD |
| 2009Q2 | 14.8 million USD | 73.2 million USD |
| 2009Q1 | 11.1 million USD | 64.5 million USD |
| 2008Q4 | 1.5 million USD | 35.8 million USD |
| 2008Q3 | 10.4 million USD | 56.6 million USD |
| 2008Q2 | 1.8 million USD | 43.5 million USD |
| 2008Q1 | 7.0 million USD | 42.7 million USD |
| 2007Q4 | 27.7 million USD | 89.6 million USD |
| 2007Q3 | 2.8 million USD | 43.6 million USD |
| 2007Q2 | -5.0 million USD | 23.2 million USD |
| 2007Q1 | -2.7 million USD | 26.4 million USD |
| 2006Q4 | 26.1 million USD | 86.9 million USD |
| 2006Q3 | -1.1 million USD | 21.9 million USD |
| 2006Q2 | -1.1 million USD | 21.9 million USD |
| 2006Q1 | -1.1 million USD | 21.9 million USD |
| 2005Q4 | 9.5 million USD | 43.8 million USD |
| 2005Q3 | 2.1 million USD | 29.0 million USD |
| 2005Q2 | 2.1 million USD | 29.0 million USD |
| 2005Q1 | 2.1 million USD | 29.0 million USD |
| 2004Q4 | 2.9 million USD | 20.9 million USD |
| 2004Q3 | 2.9 million USD | 20.9 million USD |
| 2004Q2 | 2.9 million USD | 20.9 million USD |
| 2004Q1 | 2.9 million USD | 20.9 million USD |
EBS Yearly earnings
| Date | Earnings | Revenue |
|---|---|---|
| 2023 | -223.8 million USD | 1.1 billion USD |
| 2022 | -223.8 million USD | 1.1 billion USD |
| 2021 | 219.5 million USD | 1.8 billion USD |
| 2020 | 305.8 million USD | 1.6 billion USD |
| 2019 | 54.5 million USD | 1.1 billion USD |
| 2018 | 62.7 million USD | 782.4 million USD |
| 2017 | 82.6 million USD | 560.9 million USD |
| 2016 | 51.8 million USD | 488.8 million USD |
| 2015 | 62.9 million USD | 522.8 million USD |
| 2014 | 36.7 million USD | 450.1 million USD |
| 2013 | 31.1 million USD | 312.7 million USD |
| 2012 | 23.5 million USD | 281.9 million USD |
| 2011 | 23.0 million USD | 273.4 million USD |
| 2010 | 51.7 million USD | 286.2 million USD |
| 2009 | 31.1 million USD | 234.8 million USD |
| 2008 | 20.7 million USD | 178.6 million USD |
| 2007 | 22.9 million USD | 182.9 million USD |
| 2006 | 22.8 million USD | 152.7 million USD |
| 2005 | 15.8 million USD | 130.7 million USD |
| 2004 | 11.5 million USD | 83.5 million USD |
| 2003 | 4.5 million USD | 55.8 million USD |
| 2002 | 36.4 million USD | 78.5 million USD |
| 2001 | -554000 USD | 45.3 million USD |
EBS
Price: $3.89
52 week price:
Earnings Per Share: -14.85 USD
P/E Ratio: -0.10
Exchange: NYQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Volume: 633400
Ebitda: 58.1 millionMarket Capitalization: 172.9 million